Therefore, we designed a study protocol to evaluate urinary detection of PD-L1+ kidney cells of different origins as a tool for non-invasive and therapy-attendant biomonitoring of renal complications in cancer patients receiving immunotherapy. This evidence concerns the gene CD274 and cancer.